Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free KTTAW Stock Alerts

Pasithea Therapeutics (KTTAW) Competitors

$0.0051 0.00 (-16.39%)
As of 05/14/2026 03:30 PM Eastern
Compare

KTTAW vs. AIMDW, ALVOW, ACABW, RNA, and BFRIW

Should you buy Pasithea Therapeutics stock or one of its competitors? MarketBeat compares Pasithea Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pasithea Therapeutics include Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Avidity Biosciences (RNA), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Pasithea Therapeutics compare to Ainos?

Ainos (NASDAQ:AIMDW) and Pasithea Therapeutics (NASDAQ:KTTAW) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ainos$124.16KN/AN/AN/AN/A
Pasithea TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AinosN/A N/A N/A
Pasithea Therapeutics N/A N/A N/A

In the previous week, Ainos and Ainos both had 1 articles in the media. Ainos' average media sentiment score of 1.89 equaled Pasithea Therapeutics'average media sentiment score.

Company Overall Sentiment
Ainos Very Positive
Pasithea Therapeutics Very Positive

Summary

Ainos beats Pasithea Therapeutics on 1 of the 1 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Alvotech?

Pasithea Therapeutics (NASDAQ:KTTAW) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/AN/AN/AN/A
Alvotech$586.32MN/AN/AN/AN/A

In the previous week, Alvotech had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Alvotech and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.89 beat Alvotech's score of 1.44 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Pasithea Therapeutics Very Positive
Alvotech Positive

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

Summary

Alvotech beats Pasithea Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Atlantic Coastal Acquisition Corp. II?

Pasithea Therapeutics (NASDAQ:KTTAW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

In the previous week, Pasithea Therapeutics had 1 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 1 mentions for Pasithea Therapeutics and 0 mentions for Atlantic Coastal Acquisition Corp. II. Pasithea Therapeutics' average media sentiment score of 1.89 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Pasithea Therapeutics Very Positive
Atlantic Coastal Acquisition Corp. II Neutral

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/AN/AN/AN/A
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A

Summary

Pasithea Therapeutics beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and Pasithea Therapeutics (NASDAQ:KTTAW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Avidity Biosciences had 3 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 4 mentions for Avidity Biosciences and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.89 beat Avidity Biosciences' score of 1.63 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Avidity Biosciences Very Positive
Pasithea Therapeutics Very Positive

Avidity Biosciences presently has a consensus target price of $69.42, suggesting a potential upside of 413.09%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Avidity Biosciences is more favorable than Pasithea Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avidity Biosciences
1 Sell rating(s)
11 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.37
Pasithea Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Pasithea Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Pasithea Therapeutics' return on equity of 0.00% beat Avidity Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Avidity Biosciences-3,650.39% -44.92% -39.57%
Pasithea Therapeutics N/A N/A N/A

Pasithea Therapeutics has lower revenue, but higher earnings than Avidity Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avidity Biosciences$18.62MN/A-$322.30MN/AN/A
Pasithea TherapeuticsN/AN/AN/AN/AN/A

Summary

Avidity Biosciences beats Pasithea Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Biofrontera?

Pasithea Therapeutics (NASDAQ:KTTAW) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

In the previous week, Pasithea Therapeutics and Pasithea Therapeutics both had 1 articles in the media. Pasithea Therapeutics' average media sentiment score of 1.89 beat Biofrontera's score of 1.87 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Pasithea Therapeutics Very Positive
Biofrontera Very Positive

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A N/A N/A
Biofrontera N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/AN/AN/AN/A
Biofrontera$41.71MN/AN/AN/AN/A

Summary

Pasithea Therapeutics and Biofrontera tied by winning 1 of the 2 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KTTAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KTTAW vs. The Competition

Export
MetricPasithea TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$465.98M$6.27B$12.28B
Dividend YieldN/A3.86%2.80%5.35%
P/E RatioN/A3.7620.4525.35
Price / SalesN/A7,696.51539.4773.28
Price / CashN/A13.1343.2656.33
Price / BookN/A84.689.856.86
Net IncomeN/A-$96.07M$3.55B$333.62M
7 Day PerformanceN/A0.71%0.93%0.13%
1 Month PerformanceN/A-0.02%-0.36%1.96%
1 Year PerformanceN/A67.90%36.96%32.94%

Pasithea Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KTTAW
Pasithea Therapeutics
N/A$0.01
-16.4%		N/A-70.9%$0.00N/AN/A3
AIMDW
Ainos
N/A$0.09
-17.7%		N/A-1.4%$0.00$124.16KN/A40
ALVOW
Alvotech
N/A$0.28
+29.4%		N/A-85.9%$0.00$586.32MN/A4
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15
RNA
Avidity Biosciences
2.2694 of 5 stars		$12.91
+0.3%		$69.42
+437.7%		-53.3%$0.00$18.62MN/A190

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KTTAW) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Nobody Understands Why Trump Is Invading Iran (here’s the answer)
Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decisi...
Banyan Hill Publishing | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel